Patent ID: 8343457
Filing Date: 2013-01-01
Classification: A61K,A61P

Abstract:
1. A method of identifying a patient as prodromal to a disease associated with amyloid deposition, comprising (A) administering to the patient in need thereof an effective amount of a radiolabeled compound of formula (II): or a pharmaceutically acceptable salt, of the compound, wherein: R R is C R R R provided that, when R 1 is hydrogen or —OH, R 2 is hydrogen and R 4 is — 11 CH 3 , then R 3 is C 2 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and further provided that, when R 1 is hydrogen, R 2 hydrogen and R 4 is —(CH 2 ) 3 18 F, then R 3 is C 2 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, (B) imaging said patient, then (C) administering to said patient in need thereof at least one anti-amyloid agent, (D) subsequently administering to said patient in need thereof an effective amount of a compound of formula (II), (E) imaging said patient, and (F) comparing levels of amyloid deposition in said patient before treatment with said at least one anti-amyloid agent to levels of amyloid deposition in said patient after treatment with said at least one anti-amyloid agent.